TCGA-CV-A45Z-01A-21R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.334703196
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.390
- MYC_TARGETS_V1+0.370
- MYC_TARGETS_V2+0.360
- FATTY_ACID_METABOLISM+0.160
- BILE_ACID_METABOLISM+0.120
- ADIPOGENESIS+0.090
- PANCREAS_BETA_CELLS+0.090
- PEROXISOME+0.090
- E2F_TARGETS+0.080
- WNT_BETA_CATENIN_SIGNALING+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- TNFA_SIGNALING_VIA_NFKB-0.430
- MYOGENESIS-0.420
- ANGIOGENESIS-0.380
- TGF_BETA_SIGNALING-0.380
- APICAL_JUNCTION-0.370
- HYPOXIA-0.370
- UV_RESPONSE_DN-0.370
- ESTROGEN_RESPONSE_EARLY-0.290
- INFLAMMATORY_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-A63U-01A-11R-A30B-07 | — | — | 0.876 |
| 2 | 7612ab8d-b99d-4b3b-a157-fe93e277ecf5 | — | — | 0.874 |
| 3 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.870 |
| 4 | SRR8518209 | — | C | 0.862 |
| 5 | 9da01737-be8f-4af5-9f8f-47bb892b6339 | — | — | 0.859 |
| 6 | X6b912c88.db40.4bde.8333.79829f05fade | — | cohortA4 | 0.856 |
| 7 | 20110028.LumB | — | B | 0.845 |
| 8 | TCGA-E7-A85H-01A-11R-A352-07 | — | — | 0.843 |
| 9 | SAMN03290897 | — | — | 0.840 |
| 10 | R16 | — | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.080 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |